NO311723B1 - Nye metalloproteinase inhibitorer, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem - Google Patents
Nye metalloproteinase inhibitorer, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem Download PDFInfo
- Publication number
- NO311723B1 NO311723B1 NO19985239A NO985239A NO311723B1 NO 311723 B1 NO311723 B1 NO 311723B1 NO 19985239 A NO19985239 A NO 19985239A NO 985239 A NO985239 A NO 985239A NO 311723 B1 NO311723 B1 NO 311723B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- give
- defined above
- branched
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000000034 method Methods 0.000 title claims description 34
- 239000003475 metalloproteinase inhibitor Substances 0.000 title claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
- 229910006069 SO3H Inorganic materials 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 45
- -1 D-tryptophan compound Chemical class 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 8
- 150000001412 amines Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 229930182827 D-tryptophan Natural products 0.000 claims description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 125000005554 pyridyloxy group Chemical group 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical class C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 abstract 1
- 125000004385 trihaloalkyl group Chemical group 0.000 abstract 1
- 239000000047 product Substances 0.000 description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 29
- 239000003153 chemical reaction reagent Substances 0.000 description 26
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 26
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 21
- 239000000758 substrate Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- 238000004452 microanalysis Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000003857 carboxamides Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 5
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 5
- 102000005741 Metalloproteases Human genes 0.000 description 5
- 108010006035 Metalloproteases Proteins 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 4
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- ALMLDSRUSHJWFO-HXUWFJFHSA-N (2r)-3-(1h-indol-3-yl)-2-methyl-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@@](CC=1C2=CC=CC=C2NC=1)(C)C(O)=O)C(=O)OCC1=CC=CC=C1 ALMLDSRUSHJWFO-HXUWFJFHSA-N 0.000 description 1
- ZMIGICLZMPBOHV-SFHVURJKSA-N (2r)-3-(1h-indol-3-yl)-3-methyl-2-(phenylmethoxycarbonylamino)butanoic acid Chemical compound N([C@H](C(C)(C)C=1C2=CC=CC=C2NC=1)C(O)=O)C(=O)OCC1=CC=CC=C1 ZMIGICLZMPBOHV-SFHVURJKSA-N 0.000 description 1
- YWNMBFXNRAQXHP-QGZVFWFLSA-N (2r)-3-(5-hydroxy-1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@H](CC=1C2=CC(O)=CC=C2NC=1)C(=O)O)C(=O)OCC1=CC=CC=C1 YWNMBFXNRAQXHP-QGZVFWFLSA-N 0.000 description 1
- RWUUGBCLAUENQX-GOSISDBHSA-N (2r)-3-(5-methoxy-1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@H](CC1=CNC2=CC=C(C=C21)OC)C(O)=O)C(=O)OCC1=CC=CC=C1 RWUUGBCLAUENQX-GOSISDBHSA-N 0.000 description 1
- LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SWZKXIPDGAAYKE-UHFFFAOYSA-N 1-morpholin-4-ylpropan-2-amine Chemical compound CC(N)CN1CCOCC1 SWZKXIPDGAAYKE-UHFFFAOYSA-N 0.000 description 1
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
- ISWMHRLKDDZLQU-UHFFFAOYSA-N 2-(2-morpholin-4-ylethylsulfanyl)ethanamine Chemical compound NCCSCCN1CCOCC1 ISWMHRLKDDZLQU-UHFFFAOYSA-N 0.000 description 1
- LJXTUDVFWVLPEZ-UHFFFAOYSA-N 2-(3-morpholin-4-ylpropylsulfanyl)ethanamine Chemical compound NCCSCCCN1CCOCC1 LJXTUDVFWVLPEZ-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- YYAYTNPNFKPFNG-UHFFFAOYSA-N 3-(2-methylpiperidin-1-yl)propan-1-amine Chemical compound CC1CCCCN1CCCN YYAYTNPNFKPFNG-UHFFFAOYSA-N 0.000 description 1
- FTLSZEBOECOXPS-UHFFFAOYSA-N 3-(2-morpholin-4-ylethylsulfanyl)propan-1-amine Chemical compound NCCCSCCN1CCOCC1 FTLSZEBOECOXPS-UHFFFAOYSA-N 0.000 description 1
- KKEFXWMVVJQZEA-UHFFFAOYSA-N 3-(3-morpholin-4-ylpropylsulfanyl)propan-1-amine Chemical compound NCCCSCCCN1CCOCC1 KKEFXWMVVJQZEA-UHFFFAOYSA-N 0.000 description 1
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
- DUYYFMPMGYATPO-UHFFFAOYSA-N 4-morpholin-4-ylbutan-1-amine Chemical compound NCCCCN1CCOCC1 DUYYFMPMGYATPO-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VCDNHBNNPCDBKV-DLOVCJGASA-N His-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N VCDNHBNNPCDBKV-DLOVCJGASA-N 0.000 description 1
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108090000899 Serralysin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- RXSUFCOOZSGWSW-UHFFFAOYSA-M acetyloxy-(4-aminophenyl)mercury Chemical compound CC(=O)O[Hg]C1=CC=C(N)C=C1 RXSUFCOOZSGWSW-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- ONCPEIKLFULSSA-UHFFFAOYSA-N n'-ethylbutane-1,4-diamine Chemical compound CCNCCCCN ONCPEIKLFULSSA-UHFFFAOYSA-N 0.000 description 1
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 1
- WWXPJKGWWPWBTB-UHFFFAOYSA-N n-methyl-2-morpholin-4-ylethanamine Chemical compound CNCCN1CCOCC1 WWXPJKGWWPWBTB-UHFFFAOYSA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000008364 tissue synthesis Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9714278A FR2771095B1 (fr) | 1997-11-14 | 1997-11-14 | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985239D0 NO985239D0 (no) | 1998-11-10 |
| NO985239L NO985239L (no) | 1999-05-18 |
| NO311723B1 true NO311723B1 (no) | 2002-01-14 |
Family
ID=9513364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985239A NO311723B1 (no) | 1997-11-14 | 1998-11-10 | Nye metalloproteinase inhibitorer, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6066633A (es) |
| EP (1) | EP0916671B1 (es) |
| JP (1) | JPH11209378A (es) |
| CN (1) | CN1217332A (es) |
| AT (1) | ATE212634T1 (es) |
| AU (1) | AU740313B2 (es) |
| BR (1) | BR9805014A (es) |
| CA (1) | CA2254152C (es) |
| DE (1) | DE69803648T2 (es) |
| DK (1) | DK0916671T3 (es) |
| ES (1) | ES2172101T3 (es) |
| FR (1) | FR2771095B1 (es) |
| HU (1) | HUP9802645A3 (es) |
| NO (1) | NO311723B1 (es) |
| NZ (1) | NZ332803A (es) |
| PL (1) | PL329674A1 (es) |
| PT (1) | PT916671E (es) |
| ZA (1) | ZA9810411B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2821842B1 (fr) * | 2001-03-07 | 2003-05-09 | Servier Lab | Nouveaux derives d'inhibiteurs de mettalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PE20030701A1 (es) * | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| ITMI20071163A1 (it) * | 2007-06-08 | 2008-12-09 | C4T S C A R L | Arilsolfonammidi dela beta-carbolina metodo per prepararle e composizione che le comprende |
| EP2280968A2 (en) | 2008-03-24 | 2011-02-09 | Medivation Technologies, Inc. | Pyrido [3, 4-b]indoles and methods of use |
| CN101597289B (zh) * | 2008-06-02 | 2011-09-21 | 首都医科大学 | 2-色氨酰-β-四氢咔啉-3-甲酰基氨基酸苄酯及其制备方法和应用 |
| AU2010298167B2 (en) * | 2009-09-23 | 2015-12-24 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663178A (en) * | 1995-02-06 | 1997-09-02 | Eli Lilly And Company | Tetrahydro-beta carbolines |
| DE59608740D1 (de) * | 1995-11-13 | 2002-03-21 | Hoechst Ag | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren |
| FR2748026B1 (fr) * | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
1997
- 1997-11-14 FR FR9714278A patent/FR2771095B1/fr not_active Expired - Fee Related
-
1998
- 1998-11-10 NO NO19985239A patent/NO311723B1/no unknown
- 1998-11-12 CA CA002254152A patent/CA2254152C/fr not_active Expired - Fee Related
- 1998-11-13 US US09/191,323 patent/US6066633A/en not_active Expired - Fee Related
- 1998-11-13 BR BR9805014-1A patent/BR9805014A/pt not_active IP Right Cessation
- 1998-11-13 ES ES98402806T patent/ES2172101T3/es not_active Expired - Lifetime
- 1998-11-13 DE DE69803648T patent/DE69803648T2/de not_active Expired - Fee Related
- 1998-11-13 HU HU9802645A patent/HUP9802645A3/hu unknown
- 1998-11-13 JP JP10323208A patent/JPH11209378A/ja active Pending
- 1998-11-13 DK DK98402806T patent/DK0916671T3/da active
- 1998-11-13 ZA ZA9810411A patent/ZA9810411B/xx unknown
- 1998-11-13 CN CN98122312A patent/CN1217332A/zh active Pending
- 1998-11-13 EP EP98402806A patent/EP0916671B1/fr not_active Expired - Lifetime
- 1998-11-13 NZ NZ332803A patent/NZ332803A/xx unknown
- 1998-11-13 AU AU92377/98A patent/AU740313B2/en not_active Ceased
- 1998-11-13 PT PT98402806T patent/PT916671E/pt unknown
- 1998-11-13 AT AT98402806T patent/ATE212634T1/de not_active IP Right Cessation
- 1998-11-13 PL PL98329674A patent/PL329674A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO985239L (no) | 1999-05-18 |
| AU9237798A (en) | 1999-06-03 |
| EP0916671A1 (fr) | 1999-05-19 |
| CA2254152A1 (fr) | 1999-05-14 |
| HUP9802645A2 (hu) | 1999-07-28 |
| BR9805014A (pt) | 2001-04-24 |
| JPH11209378A (ja) | 1999-08-03 |
| HU9802645D0 (en) | 1999-01-28 |
| FR2771095A1 (fr) | 1999-05-21 |
| CA2254152C (fr) | 2003-04-08 |
| CN1217332A (zh) | 1999-05-26 |
| US6066633A (en) | 2000-05-23 |
| DE69803648T2 (de) | 2002-10-31 |
| NO985239D0 (no) | 1998-11-10 |
| DK0916671T3 (da) | 2002-03-25 |
| ATE212634T1 (de) | 2002-02-15 |
| ZA9810411B (en) | 1999-05-24 |
| PT916671E (pt) | 2002-06-28 |
| DE69803648D1 (de) | 2002-03-14 |
| PL329674A1 (en) | 1999-05-24 |
| FR2771095B1 (fr) | 1999-12-17 |
| AU740313B2 (en) | 2001-11-01 |
| NZ332803A (en) | 1999-05-28 |
| EP0916671B1 (fr) | 2002-01-30 |
| ES2172101T3 (es) | 2002-09-16 |
| HUP9802645A3 (en) | 2000-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU722784B2 (en) | Arylsulfonyl hydroxamic acid derivatives | |
| US5929120A (en) | Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption | |
| CA2203618C (fr) | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| US5932579A (en) | Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use | |
| JPH05503720A (ja) | ペプチジル誘導体 | |
| EA002921B1 (ru) | Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов | |
| CA2263932A1 (en) | 1,4-heterocyclic metalloprotease inhibitors | |
| SK63498A3 (en) | Novel macrocyclic compounds as metalloprotease inhibitors | |
| WO1997025315A1 (fr) | Nouveaux derives de n-(arylsulfonyl)aminoacides ayant une affinite pour les recepteurs de la bradykinine | |
| JP2002504916A (ja) | 抗転移及び抗腫瘍活性を有するバルビツール酸誘導体 | |
| EP0605681A1 (en) | Sulphamide derivatives as metalloproteinase inhibitors | |
| CA2440931C (en) | Hiv protease inhibitors based on amino acid derivatives | |
| ES2202602T3 (es) | Tiadiazolil(tio)ureas utiles como inhibidores de la metaloproteasa matriz. | |
| JP4348014B2 (ja) | Ｎ−アリールスルホニルアミノ酸オメガ−アミド | |
| NO311723B1 (no) | Nye metalloproteinase inhibitorer, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| US6887890B2 (en) | Compounds exhibiting thrombopoietin-like activities | |
| JPH11503728A (ja) | システイン・プロテイナーゼ阻害剤として有用な新規な４−置換−３−ペプチジル−アゼチジン−２−オン誘導体 | |
| KR100445388B1 (ko) | 메탈로프로테아제 억제제, 이들의 제조 방법 및 이들을함유하는 약제학적 조성물 | |
| US5854275A (en) | Cyclic imide derivatives | |
| EP0979816B1 (fr) | Nouveaux dérivés d'acide hydroxamique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| KR100551944B1 (ko) | 신규에폭시숙신아미드유도체또는그의염 | |
| JPH08119940A (ja) | 抗ｃｃｋ活性を有するセリン誘導体 |